Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma.

Autor: Goswami S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Basu S; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Shapiro DD; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX., Karam JA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tidwell RS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Ahrar K; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Shen Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Trevino AE; Enable Medicine, Menlo Park, California., Mayer AT; Enable Medicine, Menlo Park, California., Espejo AB; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Seua C; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Macaluso MD; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Chen Y; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Liu W; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., He Z; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Yadav SS; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang Y; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX., Rao P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Zhao L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Jindal S; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publikováno v: Research square [Res Sq] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.